Archive2014

ClinicSpeak: exercise the next big thing in neurodegenerative disease

Exercise therapy; will it work in MS? #MSBlog #MSResearch #ClinicSpeak “Exercise is the next big thing in neurodegenerative diseases. It looks as if exercise delays the onset of age-related neurodegenerative diseases. It may have a similar effect in MS. Hence the interest in using exercise as a treatment for MS; to improve symptoms and possibly as a disease-modifying therapy to delay the...

Tai Chi for Balance

Azimzadeh E, Hosseini MA, Nourozi K, Davidson PM. Effect of Tai Chi Chuan on balance in women with multiple sclerosis. Complement Ther Clin Pract. 2014 . pii: S1744-3881(14)00063-2. doi: 10.1016/j.ctcp.2014.09.002. [Epub ahead of print] OBJECTIVE:To examine the effect of Tai Chi Chuan on balance in women with multiple sclerosis in Iran.DESIGN: 36 women with multiple sclerosis who...

Botox for bladder is cost effective

Hamid R, Loveman C, Millen J, Globe D, Corbell C, Colayco D, Stanisic S, Gultyaev D.Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective. Pharmacoeconomics. 2014. [Epub ahead of print] OBJECTIVES:To evaluate the cost effectiveness of BOTOX, 200 units [200 U]) for the management...

ClinicSpeak: NEDA at 7-years

Has NEDA come of age? #ClinicSpeak #MSBlog #MSResearch “Good and bad news? The good news is if you go onto a DMT and have NEDA (no evident disease activity) at 2-years it is predictive of a good disability outcome at 7 years (no disease progression). The bad news is that only a minority (8%) of MSers are rendered NEDA at 7-years. The problem with the analysis in this paper is that they did...

Saving Nerves if People take their drugs

Gnanapavan S, Grant D, Morant S, Furby J, Hayton T, Teunissen CE, Leoni V, Marta M, Brenner R, Palace J, Miller DH, Kapoor R, Giovannoni G. Biomarker report from the phase II lamotrigine trial in secondary progressive MS – neurofilament as a surrogate of disease progression.PLoS One. 2013 Aug 1;8(8):e70019. doi: 10.1371/journal.pone.0070019. OBJECTIVE: Lamotrigine trial in SPMS was a...

What does the future hold for PPMS?

Do we need to rethink PPMS?  #MSBlog #MSResearch “Now that the INFORMS (fingolimod) PPMS trial was negative we will have to rethink PPMS. It is clear that fingolimod, which is an anti-inflammatory with a potential neuroprotective effect, was not good enough. Is this because PPMS is not inflammatory? No, PPMS is very inflammatory; I have previously discussed the post-mortem findings of PPMS...

Prognosis of MS

Kerbrat A, Hamonic S, Leray E, Tron I, Edan G, Yaouanq J; within the West Neuroscience Network of Excellence (WENNE).Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.Eur J Neurol. 2014. doi: 10.1111/ene.12600. [Epub ahead of print]BACKGROUND AND PURPOSE: Multiple sclerosis (MS) prognosis remains a challenge for both...

Advent Calendar-25

Advent calendars normally end on the 24th ready for Christmas Eve. Our Advent Calendar was to advertise our research day on March 21st 2015 in Central London and showed how we are trying to develop drugs for symptom control in the process. It just leaves us to say have a Happy Christmas day…. What are you doing looking at the Computer? You should be tucking into some Christmas Pub and...

6th Research Day

     The Advent Calender served to announce the 6th Research Day
          Alison has been working behind the Scenes and She will                                  update this very soon.

Translate

Categories

Recent Posts

Recent Comments

Archives